Mathes Company Inc. Reduces Holdings in Johnson & Johnson (JNJ)

Share on StockTwits

Mathes Company Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,862 shares of the company’s stock after selling 980 shares during the period. Johnson & Johnson accounts for 2.5% of Mathes Company Inc.’s investment portfolio, making the stock its 5th biggest position. Mathes Company Inc.’s holdings in Johnson & Johnson were worth $3,983,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Horan Securities Inc. increased its position in Johnson & Johnson by 122.3% during the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. increased its position in Johnson & Johnson by 20.7% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 80 shares in the last quarter. FNY Investment Advisers LLC increased its position in Johnson & Johnson by 594.4% during the fourth quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after buying an additional 428 shares in the last quarter. CKW Financial Group increased its position in Johnson & Johnson by 18.8% during the fourth quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after buying an additional 128 shares in the last quarter. Finally, Mackey Komara & Dankovich LLC purchased a new position in Johnson & Johnson during the fourth quarter worth $148,000. 66.91% of the stock is owned by institutional investors.

Shares of NYSE:JNJ opened at $138.12 on Wednesday. The firm has a market capitalization of $371.88 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 2.40 and a beta of 0.67. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The business’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.06 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date of this dividend is Friday, May 24th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s payout ratio is 44.01%.

A number of equities research analysts have recently commented on JNJ shares. Credit Suisse Group lifted their price objective on Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Raymond James lifted their price objective on Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. BMO Capital Markets lifted their price objective on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Finally, Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective for the company in a research report on Wednesday, March 27th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $147.30.

COPYRIGHT VIOLATION NOTICE: “Mathes Company Inc. Reduces Holdings in Johnson & Johnson (JNJ)” was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4349001/mathes-company-inc-reduces-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Put Option

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hurco Companies, Inc.  Plans $0.12 Quarterly Dividend
Hurco Companies, Inc. Plans $0.12 Quarterly Dividend
China Yuchai International Limited  to Issue Annual Dividend of $0.85
China Yuchai International Limited to Issue Annual Dividend of $0.85
Aberdeen Smaller Coms High Incm Trst PLC  To Go Ex-Dividend on July 4th
Aberdeen Smaller Coms High Incm Trst PLC To Go Ex-Dividend on July 4th
Porvair plc Plans Dividend of GBX 1.70
Porvair plc Plans Dividend of GBX 1.70
Polar Capital Holdings plc  To Go Ex-Dividend on July 4th
Polar Capital Holdings plc To Go Ex-Dividend on July 4th
Bank of Nova Scotia  to Issue Quarterly Dividend of $0.87 on  July 29th
Bank of Nova Scotia to Issue Quarterly Dividend of $0.87 on July 29th


© 2006-2019 Ticker Report